Trial site
Neuropsychiatric Research Center of Southwest Florida
- 9running trials
- 11closed trials
The trials here
What the 20 trials at this site are about, from their registry records.
- Conditions
- Alzheimer disease20 trials
- Mild cognitive impairment4 trials
- Frontotemporal dementia1 trial
- Lewy body dementia1 trial
- Phase
- Phase 39 trials
- Phase 28 trials
- Phase 1/21 trial
- Status
- Completed7 trials
- Active, not recruiting5 trials
- Terminated4 trials
- Recruiting3 trials
- Enrolling by invitation1 trial
- Lead sponsor
- Eli Lilly and Company7 trials
- Cassava Sciences, Inc.4 trials
- Biogen2 trials
- Cognito Therapeutics, Inc.2 trials
- Bristol-Myers Squibb1 trial
- and 4 more
Running trials
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Recruiting
Recruiting
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
Active, not recruiting
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Active, not recruiting
Enrolling by invitation
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
Active, not recruiting
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
Active, not recruiting
Active, not recruiting
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Alzheimer disease4 recruiting
- Mild cognitive impairment2 recruiting
- Lewy body dementia1 recruiting
Closed trials
Completed
A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease
Completed
A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)
Terminated
Open-label Extension for Phase 3 Clinical Trials of Simufilam
Completed
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Terminated
A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease
Terminated
Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease
Completed
Completed
Completed
SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)
Completed
Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients
Terminated
Site data: ClinicalTrials.govUpdated 18 Nov 2026